Immunitybio, INC Form 4 insider transactions

Cheryl Cohen, a Director at ImmunityBio, Inc., reported transactions involving the sale of company stock.

ImmunityBio, Inc. Director Christobel Selecky reported transactions involving the acquisition and sale of common stock, executed under a pre-arranged Rule 10b5-1 trading plan.

ImmunityBio Director Christobel Selecky executed a series of stock option exercises and sales under a pre-arranged Rule 10b5-1 trading plan.

ImmunityBio Director Barry J. Simon sold 25,000 shares of common stock for approximately $7.88 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Director Michael D. Blaszyk was granted 65,600 stock options in ImmunityBio, Inc. as part of the company's 2025 Equity Incentive Plan.

Director Bruce Wendel was granted 65,600 stock options in ImmunityBio, Inc. under the company's 2025 Equity Incentive Plan.

Director Linda Maxwell was granted 65,600 stock options in ImmunityBio, Inc. with a strike price of $7.25.

Director Wesley Clark was granted 65,600 stock options in ImmunityBio, Inc. as part of the company's 2025 Equity Incentive Plan.

ImmunityBio director Cheryl Cohen was granted 65,600 stock options as part of the company's 2025 Equity Incentive Plan.

Director Christobel Selecky was granted 65,600 stock options in ImmunityBio, Inc. as part of the company's 2025 Equity Incentive Plan.

Director Barry J. Simon sold 23,033 shares of ImmunityBio, Inc. common stock via a pre-arranged 10b5-1 trading plan.

Patrick Soon-Shiong, a director and significant shareholder of ImmunityBio, Inc., has converted a $25 million promissory note into over 4.6 million shares of common stock.

ImmunityBio Director Barry J. Simon sold 75,000 shares of common stock for approximately $12.01 per share under a pre-arranged trading plan.

ImmunityBio Director Christobel Selecky exercised stock options and immediately sold 25,000 shares of common stock for a profit.

ImmunityBio's Chief Financial Officer, David C. Sachs, reported the vesting of restricted stock units and subsequent share transactions.

Patrick Soon-Shiong, a key insider at ImmunityBio, converted restricted stock units into common stock and subsequently sold a portion to cover tax obligations.

ImmunityBio's Chief Accounting Officer, Regan Lauer, reported the vesting of restricted stock units and a subsequent sale of shares for tax obligations.

ImmunityBio CEO Richard Adcock reported the vesting of 152,439 restricted stock units and the subsequent sale of 77,560 shares for tax purposes.

ImmunityBio Director Barry J. Simon reported multiple transactions including sales of common stock and the vesting and subsequent tax-related disposition of restricted stock units.

Patrick Soon-Shiong, a Director and 10% Owner of ImmunityBio, Inc., reported the vesting of Restricted Stock Units and subsequent share disposition for tax purposes.

ImmunityBio's Chief Financial Officer, David C. Sachs, reported the vesting and exercise of restricted stock units and subsequent tax-related share disposition.

ImmunityBio's Chief Accounting Officer, Regan J. Lauer, reported the vesting of restricted stock units and a subsequent sale of shares for tax purposes.

ImmunityBio CEO Richard Adcock vested 274,122 restricted stock units, acquiring common stock and selling a portion to cover tax liabilities.

ImmunityBio Director Barry J. Simon reported the sale of 151,967 shares of common stock on January 20, 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

ImmunityBio Director Christobel Selecky exercised stock options and subsequently sold shares in January 2026, pursuant to a pre-arranged 10b5-1 trading plan.

ImmunityBio's Chief Financial Officer, David C. Sachs, reported the vesting of restricted stock units and subsequent disposition of shares for tax withholding.

ImmunityBio CEO Richard Adcock reported the vesting of restricted stock units and subsequent tax-related share disposals on December 31, 2025.

ImmunityBio Director Bruce Wendel reported the acquisition of 146,020 stock options with an exercise price of $2.36, vesting through December 2028.

ImmunityBio, Inc. has reported that Director Christobel Selecky was granted 162,786 stock options with an exercise price of $2.84, vesting by June 2026.

ImmunityBio, Inc. Director Cheryl Cohen was granted 162,786 stock options with an exercise price of $2.84, aligning her interests with shareholder value.